- Previous Rank20
- Revenues ($M)100,887
- Revenue Percent Change-3.6%
- Profits ($M)2,008
- Profits Percent Change8.8%
- Market Value (as of March 31, 2015)63,237
Express Scripts, a full service pharmacy benefits manager, has been benefitting from industry consolidation that has cut costs and boosted their bargaining strength as pharmaceutical companies release high-priced treatments for hepatitis C and high cholesterol. Express Scripts led the wave of consolidation when it bought Medco Health Solutions for almost $30 billion in 2012. The deal doubled its revenues and positioned the company as the No. 1 pharmacy benefits manager. The St. Louis, Mo.-based company has also benefitted from more insured patients, a result of the Affordable Care Act. Express Scripts has used its industry-leading position to wring out savings on high-cost specialty drugs for its users, which will become more necessary as more innovative treatments come on the market. Specialty pharmacy is expect to grow by about 20% over the next few years and customers will rely on PBM’s to help them better manage this spend.
Company Info
| CEO | Timothy C. Wentworth |
| Industry | Health Care: Pharmacy and Other Services |
| Sector | Health Care |
| HQ Location | St. Louis, MO |
| Website | http://www.express-scripts.com |
| Years on List | 16 |
Key Financials (last fiscal year)
| $ millions | % change | |
|---|---|---|
| Revenues ($M) | 100,887 | -3.6% |
| Profits ($M) | 2,008 | 8.8% |
| Total Stockholder Equity | 20,054 | - |
| Employees | 29,500 | - |
| Market Value (as of March 31, 2015) | 63,237 | - |
Profit Ratios
| Profit as % of Revenues | 2% |
| Profits as % of Assets | 3.7% |
| Profits as % of Stockholder Equity | 10% |
Earnings Per Share (last fiscal year)
| Earnings Per Share ($) | 2.64 |
| EPS % Change (from 2013) | 17.3% |
| EPS % Change (5 year annual rate) | 11.2% |
| EPS % Change (10 year annual rate) | 19.4% |
Total Return
| Total Return to Investors (2014) | 20.5% |
| Total Return to Investors (5 year, annualized) | 14.4% |
| Total Return to Investors (10 year, annualized) | 24.4% |